Csl Limited · ASX:CSL
Csl — Shareholder Meeting (October 2002)
17 slides from Csl's shareholder meeting presentation, Oct 17, 2002
Slide 1: Annual General Meeting 2002
ANNUAL GENERAL MEETING 2002 lea OUR BUSINESS IS HEALTH CARE
Slide 2: CSL Group Annual General Meeting Presentation
CSL GROUP Annual General Meeting Presentation 17 October 2002 CSL Group 1
Slide 3: CSL's Record Year
CSL’s Record Year • Strong Financial Performance – Revenues increased by 58% to $1,350m – EBITDA increased by 44% to $299m – NPAT (before Amort) increased by 60% to $164m – NPAT increased by record 58% to $124m – R&D investment increased by 15% to $93m CSL Group 2
Slide 4: Sales by Business Unit - $1,336m
Sales by Business Unit - $1,336m Pharmaceutical Animal Health 16% 5% Biosciences CSL Bioplasma 11% 12% Human Health Plasma Services 21% ZLB Bioplasma 35% $Australian CSL Group 3
Slide 5: 10 Year Total Revenues
10 Year Total Revenues $1,500 1350 $1,250 $1,000 CAGR 26% 855 $750 $500 171 $250 $0 1993 Listed 1994 2001 2002 For the year ended 30 June CSL Group 4
Slide 6: 10 Year Operating Profit After Tax
10 Year Operating Profit After Tax $140 123.8 $120 $100 CAGR 28% 78.2 $80 $60 $40 13.8 $20 $0 1993 Listed 1994 2001 2002 For the year ended 30 June CSL Group 5
Slide 7: Share Price Performance
Share Price Performance • Relative share price performance since January 2001 – Major pharma (37%) – Speciality pharma (37%) – CSL (44%) – Plasma (46%) – Biotech (49%) • Average annual total return to CSL shareholders – Total return (since the Float) - 50% pa CSL Group 6
Slide 8: ZLB - US Market
ZLB - US Market • IVIG pricing – average ZLB price for current formulation is forecast to reduce – price improvement expected 2nd half: Nano, 12g • Development of market – Competition high with supply/demand imbalance – Broaden Carimune usage to “home care market” • Key recruitments finalised CSL Gr
Slide 9: ZLB - European Market
ZLB - European Market • IVIG pricing – average ZLB prices are US$30 - US$35 per gram • Sandoglobulin – registrations, trademark and customer lists – launch Sept 2002 with rollout over 4-6 months • European subsidiaries established • Key recruitments - country managers • RoW markets via distributor n
Slide 10: Plasma Services
Plasma Services • Successfully integrated into Group – commenced operations Sept 2001 – recorded sales of $282m – collections higher than forecast due to US economy CSL Group 9
Slide 11: Pharmaceutical
Pharmaceutical • Sales $219.9 million, 18% sales growth • Strong performance in in-licensed products • Build on influenza vaccine expertise • Creating value from R&D assets CSL Group 10
Slide 12: New Product Development
New Product Development • Merck HPV Vaccine – Phase IIb efficacy data to be published – Worldwide Phase III Program under way – Australian site opened August CSL Group 11
Slide 13: JRH Biosciences
JRH Biosciences • Sales - $145.9m, growth of 34% • Margins - continue to improve • Demand - expected to remain strong • Facility expansion – Pennsylvania, US dry powdered media expansion completion late 2002 – Andover, UK liquid media completion early 2003 CSL Group 12
Slide 14: Animal Health
Animal Health • Sales - $60.9m, underlying growth 10% • US sales - growth of 12% with increased market share in bovine and canine vaccines • Successful launch of Gudair in Australia • New leptospiral vaccine facility – construction well advanced – commissioning scheduled for late 2002 CSL Group 13
Slide 15: Current Financial Year
Current Financial Year • 1st half impacted by – European establishment – IVIG price reductions on current IVIG presentations – Forex • 2nd half improved by – European sales – IVIG - new presentations in the US – Forex issue remains CSL Group 14
Slide 16: Drivers of Medium Term Growth
Drivers of Medium Term Growth • Increase plasma scale and throughput • Expansion of global niche businesses • New and improved products – Improved IVIG – Anti-D - Rhophylac™ – Factor VIII - Biostate™ – Fibrin Bandage (partner with ANRC) • Licensing revenue CSL Group 15
Slide 17: Annual General Meeting 2002
ANNUAL GENERAL MEETING 2002 lea OUR BUSINESS IS HEALTH CARE